VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal

VOLITIONRX LTD

2025-Q2 EPS reported -$0.12 revenue$653,073

Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.
Net loss decreased 11% in Q2 and 24% in H1 vs prior year; operating cash burn down 30% to $10.6M in H1.
Cash & equivalents $2.3M at June 30, 2025; received $1.2M from direct offering post-quarter (director participation).
Management expects first human diagnostics out-licensing deal in Q3 2025; confidential discussions with >10 companies.
Conference call scheduled for August 15, 2025 at 8:30 a.m. ET.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.